Candel Therapeutics, Inc. (CADL) Stock Forecast
CADL analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 9 analysts
- Price target
- $21.75 average of analyst targets
- Upside to target
- +165.6% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.30
- 52-week range
- $4.42 – $13.75
CADL analyst ratings
9 analystsNumber of analysts at each rating.
CADL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CADL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.31 | −$0.33 | −$0.29 | −$0.23 | −37.0% | 2 |
| Current fiscal year (2026) | −$1.08 | −$1.28 | −$0.74 | −$0.88 | −23.3% | 3 |
| Next fiscal year (2027) | −$0.62 | −$1.47 | $0.22 | −$1.08 | +42.1% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CADL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 7 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 7 |
| Next fiscal year (2027) | $44.3M | $0 | $128.8M | 0.0% | 8 |
CADL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CADL revenue: reported and forecast
CADL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | −$0.26 | −$0.25 | −$0.25 | −$0.31 | — | 0 up · 1 down |
| Current fiscal year (2026) | −$0.87 | −$0.90 | −$1.00 | −$1.08 | −$1.08 | +23.7% | 0 up · 1 down |
| Next fiscal year (2027) | $0.22 | −$0.60 | −$0.62 | −$0.62 | −$0.62 | −384.1% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CADL earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CADL beat in 2 of 10.
What analysts expect from CADL
9 analysts cover Candel Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $21.75, 165.6% above the latest close of $8.19. Analysts expect earnings of −$1.08 per share for 2026, −23.3% from a year earlier. For 2027 the average estimate is −$0.62 per share on revenue of $44.3 million. Candel Therapeutics beat the EPS estimate in 2 of the last 10 quarters.
Related: CADL income statement, CADL key metrics, CADL chart. See the CADL stock overview for the latest quote and news.
CADL forecast FAQ
What is Candel Therapeutics's price target?
The average analyst price target for Candel Therapeutics is $21.75, 165.6% above the latest close of $8.19.
Is Candel Therapeutics a buy, hold or sell?
Of 9 analysts covering Candel Therapeutics, 9 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Candel Therapeutics's EPS forecast?
Analysts forecast −$1.08 per share for 2026 (range −$1.28 to −$0.74); for 2027 the estimate is −$0.62.
When does Candel Therapeutics report earnings?
Candel Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens; the EPS estimate is $-0.30.
Does Candel Therapeutics usually beat earnings estimates?
Candel Therapeutics reported EPS at or above the analyst estimate in 2 of the last 10 quarters.